[{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"CAR-Treg cell therapy","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Mogrify \/ Sangamo","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ Sangamo"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"AAV-Based Genetic Medicine","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Mogrify \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Mogrify \/ Astellas Pharma"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Venture Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Mogrify","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Mogrify \/ Astellas Venture Management","highestDevelopmentStatusID":"4","companyTruncated":"Mogrify \/ Astellas Venture Management"}]

Find Clinical Drug Pipeline Developments & Deals by Mogrify

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The financing will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 02, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Astellas Venture Management

                          Deal Size : $46.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : As part of the collaboration, Astellas Gene Therapies, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus based genetic medicine and translational capabilities to complete experiments in pre-clinical...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 05, 2022

                          Lead Product(s) : AAV-Based Genetic Medicine

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Discovery

                          Sponsor : Astellas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Mogrify will discover and optimize cell conversion technology from iPSCs or ESCs to regulatory T cells. Sangamo will use Mogrify’s technology to create Tregs from iPSCs or ESCs.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 21, 2020

                          Lead Product(s) : CAR-Treg cell therapy

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Sangamo Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank